Spots Global Cancer Trial Database for Study to Investigate the Efficacy, Safety and Tolerability of AZD1152 Alone and in Combination With Low Dose Cytosine Arabinoside (LDAC)in Acute Myeloid Leukaemia (AML) Patients
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study to Investigate the Efficacy, Safety and Tolerability of AZD1152 Alone and in Combination With Low Dose Cytosine Arabinoside (LDAC)in Acute Myeloid Leukaemia (AML) Patients
Official Title: A Randomised, Open-label, Multi-centre, 2-stage, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of AZD1152 Alone and in Combination With Low Dose Cytosine Arabinoside (LDAC) in Comparison With LDAC Alone in Patients Aged ≥ 60 With Newly Diagnosed Acute Myeloid Leukaemia (AML)
Study ID: NCT00952588
Conditions
Study Description
Brief Summary: The purpose of this study is to assess the efficacy, safety and tolerability of AZD1152 alone and in combination with low dose cytosine arabinoside (LDAC) in comparison with LDAC alone in AML patients.
Detailed Description:
Keywords
Eligibility
Minimum Age: 60 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Research Site, Atlanta, Georgia, United States
Research Site, Chicago, Illinois, United States
Research Site, New York, New York, United States
Research Site, Cleveland, Ohio, United States
Research Site, Portland, Oregon, United States
Research Site, Greenville, South Carolina, United States
Research Site, Nashville, Tennessee, United States
Research Site, Houston, Texas, United States
Research Site, Westmead, New South Wales, Australia
Research Site, Herston, Queensland, Australia
Research Site, Melbourne, Victoria, Australia
Research Site, Parkville, Victoria, Australia
Research Site, Angers Cedex 01, , France
Research Site, Clermont-ferrand, , France
Research Site, Grenoble Cedex 09, , France
Research Site, Lyon Cedex 03, , France
Research Site, Marseille Cedex 09, , France
Research Site, Nantes, , France
Research Site, Duisburg, , Germany
Research Site, Erlangen, , Germany
Research Site, Frankfurt, , Germany
Research Site, Munster, , Germany
Research Site, Villingen-schwenningen, , Germany
Research Site, Bologna, BO, Italy
Research Site, Genova, GE, Italy
Research Site, Orbassano, TO, Italy
Research Site, Udine, UD, Italy
Research Site, Roma, , Italy
Research Site, Nagoya, Aichi, Japan
Research Site, Yoshida-gun, Fukui, Japan
Research Site, Maebashi, Gunma, Japan
Research Site, Isehara, Kanagawa, Japan
Research Site, Yokohama, Kanagawa, Japan
Research Site, Chuo, Tokyo, Japan
Research Site, Fukuoka, , Japan
Research Site, Brasov, , Romania
Research Site, TG Mures, , Romania
Research Site, Oviedo, Asturias, Spain
Research Site, Badalona(barcelona), Cataluna, Spain
Research Site, Barcelona, Cataluna, Spain
Research Site, Madrid, Comunidad DE Madrid, Spain
Research Site, Valencia, Comunidad Valenciana, Spain
Research Site, Majadahonda, Madrid, Spain
Research Site, Brighton, , United Kingdom
Research Site, London, , United Kingdom
Contact Details
Name: Paul Stockman
Affiliation: AstraZeneca
Role: STUDY_DIRECTOR
Name: Hagop Kantarjian
Affiliation: M.D. Anderson Cancer Center
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
